2019 |
08/09 | 15:00 営業外費用の計上に関するお知らせ |
08/09 | 15:00 2020年3月期第1四半期決算短信〔日本基準〕(連結) |
08/08 | 230 | 232 | 228 | 230 | 0% | 158,300 | 163億6435万 | -1.71% |
08/07 | 232 | 234 | 229 | 230 | -0.86% | 164,600 | 163億6435万 | -1.71% |
08/06 | 215 | 232 | 215 | 232 | +4.04% | 397,200 | 165億665万 | -0.85% |
08/05 | 225 | 226 | 217 | 223 | -1.76% | 468,100 | 158億6631万 | -4.7% |
08/02 | 230 | 231 | 226 | 227 | -2.58% | 255,500 | 161億5091万 | -2.99% |
08/01 | 232 | 236 | 232 | 233 | -0.43% | 198,000 | 165億7780万 | -0.43% |
07/31 | 235 | 237 | 233 | 234 | -0.85% | 132,500 | 166億4895万 | +0.43% |
07/30 | 237 | 238 | 234 | 236 | -0.42% | 156,000 | 167億9125万 | +1.72% |
07/29 | 232 | 237 | 232 | 237 | +1.72% | 136,200 | 168億6240万 | +2.16% |
07/26 | 237 | 238 | 233 | 233 | -2.51% | 220,300 | 165億7780万 | +0.87% |
07/25 | 238 | 240 | 236 | 239 | +0.42% | 189,200 | 170億470万 | +3.91% |
07/24 | 237 | 243 | 234 | 238 | +0.85% | 411,900 | 169億3355万 | +3.93% |
07/23 | 232 | 236 | 232 | 236 | +1.72% | 148,400 | 167億9125万 | +3.51% |
07/22 | 230 | 232 | 227 | 232 | +1.31% | 201,200 | 165億665万 | +2.2% |
07/19 | 226 | 232 | 226 | 229 | +0.88% | 165,500 | 162億9321万 | +0.88% |
07/18 | 230 | 233 | 227 | 227 | -2.58% | 247,600 | 161億5091万 | +0.44% |
07/17 | 232 | 238 | 232 | 233 | +0.43% | 266,900 | 165億7780万 | +3.1% |
07/16 | 232 | 235 | 230 | 232 | -1.28% | 187,600 | 165億665万 | +2.65% |
07/12 | 240 | 241 | 234 | 235 | -2.08% | 414,700 | 167億2010万 | +4.44% |
07/11 | 241 | 243 | 239 | 240 | -0.83% | 212,300 | 170億7585万 | +6.67% |
07/10 | 15:00 Bioserve Biotechnologies India Pvt.Ltd.の株式の取得(完全子会社化)に関するお知らせ |
07/10 | 240 | 245 | 239 | 242 | +0.41% | 235,100 | 172億1815万 | +8.04% |
07/09 | 248 | 254 | 240 | 241 | 0% | 1,444,300 | 171億4700万 | +8.56% |
07/08 | 16:00 再生医療製品ステムカイマルの開発費用に対する希少疾病用再生医療等製品試験研究助成金交付決定のお知らせ |
07/08 | 241 | 248 | 239 | 241 | -1.23% | 645,000 | 171億4700万 | +9.05% |
07/05 | 230 | 244 | 229 | 244 | +6.09% | 922,200 | 173億6045万 | +11.42% |
07/04 | 230 | 231 | 227 | 230 | 0% | 187,400 | 163億6435万 | +5.5% |
07/03 | 237 | 237 | 224 | 230 | -0.86% | 613,300 | 163億6435万 | +5.5% |
07/02 | 228 | 235 | 226 | 232 | +3.57% | 632,000 | 165億665万 | +6.91% |
07/01 | 225 | 227 | 224 | 224 | 0% | 356,600 | 159億3746万 | +3.23% |
06/28 | 219 | 225 | 219 | 224 | +2.28% | 392,400 | 159億3746万 | +3.23% |
06/27 | 218 | 220 | 216 | 219 | +0.46% | 160,700 | 155億8171万 | +0.92% |
06/26 | 213 | 220 | 213 | 218 | +0.93% | 278,200 | 155億1056万 | +0.46% |
06/25 | 218 | 220 | 213 | 216 | -0.92% | 232,300 | 153億6826万 | -0.46% |
06/24 | 221 | 225 | 217 | 218 | +2.35% | 760,600 | 155億1056万 | 0% |
06/21 | 15:00 合弁会社Fox Chase Bioserve Pvt.Ltd.(インド)設立に関するお知らせ |
06/21 | 219 | 220 | 213 | 213 | -3.18% | 297,500 | 151億5482万 | -2.29% |
06/20 | 216 | 221 | 213 | 220 | +2.33% | 289,700 | 156億5286万 | +0.46% |
06/19 | 214 | 217 | 212 | 215 | +1.42% | 190,600 | 152億9711万 | -1.83% |
06/18 | 219 | 219 | 211 | 212 | -2.75% | 314,100 | 150億8367万 | -3.64% |
06/17 | 15:00 AMEDプロジェクト「再生医療の産業化に向けた細胞製造・加工システムの開発」の2018年度交付額確定に関するお知らせ |
06/17 | 221 | 221 | 216 | 218 | 0% | 213,900 | 155億1056万 | -1.36% |
06/14 | 218 | 221 | 217 | 218 | 0% | 232,100 | 155億1056万 | -1.8% |
06/13 | 10:00 Cell Innovation Partners, Ltd.によるSymic Holdings, LLCへの出資実行のお知らせ |
06/13 | 222 | 224 | 216 | 218 | -3.11% | 361,300 | 155億1056万 | -2.24% |
06/12 | 220 | 227 | 220 | 225 | +1.81% | 349,900 | 160億861万 | +0.45% |
06/11 | 220 | 224 | 216 | 221 | +0.45% | 340,900 | 157億2401万 | -1.78% |
06/10 | 219 | 222 | 217 | 220 | +0.46% | 333,100 | 156億5286万 | -2.65% |
06/07 | 215 | 219 | 213 | 219 | +2.82% | 420,200 | 155億8171万 | -3.52% |
06/06 | 226 | 227 | 212 | 213 | +2.4% | 1,697,900 | 151億5482万 | -6.58% |
06/05 | 18:00 当社と東京工業大学による共同研究開発計画の関東経済産業局公募事業への採択に関するお知らせ |
06/05 | 208 | 212 | 206 | 208 | +0.97% | 262,100 | 147億9907万 | -9.17% |
06/04 | 205 | 208 | 203 | 206 | +0.49% | 446,000 | 146億5677万 | -10.43% |
06/03 | 209 | 211 | 204 | 205 | -4.21% | 468,500 | 145億8562万 | -11.64% |
05/31 | 10:00 営業外利益(持分法による投資利益)の発生に関するお知らせ |
05/31 | 216 | 220 | 213 | 214 | -0.47% | 474,400 | 152億2596万 | -8.55% |
05/30 | 225 | 231 | 213 | 215 | -4.02% | 1,132,800 | 152億9711万 | -8.51% |
05/29 | 226 | 228 | 221 | 224 | -2.18% | 378,200 | 159億3746万 | -5.08% |
05/28 | 223 | 229 | 221 | 229 | +3.62% | 435,100 | 162億9321万 | -3.38% |
05/27 | 218 | 222 | 218 | 221 | +0.45% | 207,200 | 157億2401万 | -6.75% |
05/24 | 216 | 222 | 214 | 220 | -0.45% | 523,700 | 156億5286万 | -7.56% |
05/23 | 224 | 225 | 220 | 221 | -1.78% | 500,300 | 157億2401万 | -7.53% |
05/22 | 224 | 228 | 222 | 225 | +0.9% | 445,000 | 160億861万 | -6.25% |
05/21 | 229 | 229 | 223 | 223 | -1.76% | 385,300 | 158億4780万 | -7.47% |
05/20 | 232 | 234 | 226 | 227 | -1.3% | 288,400 | 161億3207万 | -5.81% |
05/17 | 229 | 233 | 228 | 230 | +1.32% | 376,000 | 163億4526万 | -4.96% |
05/16 | 232 | 234 | 227 | 227 | -2.16% | 465,300 | 161億3207万 | -6.2% |
05/15 | 235 | 238 | 228 | 232 | -2.52% | 793,400 | 164億8740万 | -4.53% |
05/14 | 15:00 2019年3月期決算短信〔日本基準〕(連結) |
05/14 | 15:00 営業外収益の計上に関するお知らせ |
05/14 | 235 | 241 | 228 | 238 | -0.83% | 757,700 | 169億1380万 | -2.06% |
05/13 | 10:00 殿町・リプロセル再生医療センターの開設について |
05/13 | 258 | 258 | 238 | 240 | -2.83% | 1,132,600 | 170億5593万 | -1.23% |
05/10 | 242 | 248 | 238 | 247 | +2.92% | 542,100 | 175億5339万 | +1.65% |
05/09 | 15:00 営業外費用(持分法による投資利益の減少)の計上及び2019年3月期通期個別業績予想と前期実績との差異に関するお知らせ |
05/09 | 252 | 252 | 240 | 240 | -5.14% | 654,300 | 170億5593万 | -1.23% |
05/08 | 242 | 258 | 238 | 253 | +2.85% | 976,900 | 179億7979万 | +4.12% |
05/07 | 248 | 248 | 244 | 246 | -0.4% | 490,400 | 174億8233万 | +1.23% |
04/26 | 244 | 250 | 239 | 247 | +2.07% | 406,500 | 175億5339万 | +1.65% |
04/25 | 15:00 Bioserve Biotechonologies India Pvt LtdとHanugen Therapeuticsとの遺伝子治療のためのオリゴヌクレオチドの製造のためのパートナーシップの締結のお知らせ |
04/25 | 241 | 246 | 240 | 242 | -0.82% | 369,900 | 171億9806万 | -0.41% |
04/24 | 239 | 244 | 237 | 244 | +2.09% | 535,400 | 173億4019万 | 0% |
04/23 | 249 | 250 | 237 | 239 | -5.53% | 818,100 | 169億8486万 | -2.05% |
04/22 | 252 | 260 | 251 | 253 | -0.78% | 598,300 | 179億7979万 | +3.27% |
04/19 | 248 | 262 | 245 | 255 | +4.08% | 1,181,000 | 181億2192万 | +4.08% |
04/18 | 236 | 276 | 233 | 245 | +2.08% | 3,484,700 | 174億1126万 | -0.41% |
04/17 | 239 | 241 | 235 | 240 | +0.84% | 354,300 | 170億5593万 | -2.83% |
04/16 | 241 | 244 | 238 | 238 | -1.65% | 206,000 | 169億1380万 | -3.64% |
04/15 | 233 | 243 | 233 | 242 | +1.26% | 448,600 | 171億9806万 | -2.42% |
04/12 | 248 | 248 | 238 | 239 | -2.45% | 417,500 | 169億8486万 | -3.63% |
04/11 | 248 | 250 | 242 | 245 | -0.41% | 346,200 | 174億1126万 | -1.21% |
04/10 | 239 | 246 | 239 | 246 | +1.65% | 270,000 | 174億8233万 | -1.2% |
04/09 | 246 | 246 | 239 | 242 | +0.83% | 291,700 | 171億9806万 | -3.2% |
04/08 | 15:00 REPROCELL USA Inc.におけるISO9001:2015認証取得のお知らせ |
04/08 | 241 | 243 | 238 | 240 | +0.42% | 218,900 | 170億5593万 | -4% |
04/05 | 237 | 241 | 234 | 239 | +0.84% | 336,200 | 169億8486万 | -4.78% |
04/04 | 238 | 242 | 233 | 237 | -0.42% | 405,600 | 168億4273万 | -5.58% |
04/03 | 236 | 241 | 234 | 238 | +1.71% | 323,100 | 169億1380万 | -5.56% |
04/02 | 243 | 245 | 234 | 234 | -4.1% | 641,500 | 166億2953万 | -7.51% |
04/01 | 246 | 248 | 240 | 244 | +0.83% | 371,900 | 173億4019万 | -3.94% |
03/29 | 244 | 244 | 239 | 242 | 0% | 246,100 | 171億9806万 | -5.1% |
03/28 | 246 | 246 | 238 | 242 | -3.2% | 465,200 | 171億9806万 | -5.1% |
03/27 | 251 | 253 | 244 | 250 | +1.63% | 537,800 | 177億6659万 | -1.96% |
03/26 | 242 | 248 | 241 | 246 | +3.8% | 391,600 | 174億8233万 | -3.53% |
03/25 | 244 | 245 | 236 | 237 | -5.58% | 735,000 | 168億4273万 | -7.06% |
03/22 | 259 | 260 | 251 | 251 | -3.46% | 520,800 | 178億3766万 | -1.18% |
03/20 | 259 | 263 | 257 | 260 | 0% | 505,600 | 184億7726万 | +3.17% |
03/19 | 267 | 267 | 258 | 260 | -1.89% | 518,300 | 184億7726万 | +3.59% |
03/18 | 265 | 265 | 258 | 265 | +2.32% | 560,300 | 188億3259万 | +6.43% |
03/15 | 263 | 272 | 259 | 259 | -2.63% | 1,087,400 | 184億619万 | +4.86% |
03/14 | 264 | 268 | 258 | 266 | +0.76% | 786,100 | 189億366万 | +8.13% |
03/13 | 254 | 265 | 254 | 264 | +2.33% | 890,300 | 187億6152万 | +8.2% |
03/12 | 252 | 265 | 248 | 258 | +4.03% | 1,171,300 | 183億3512万 | +6.61% |